

7:00 am – 4:30 pm
Grand Foyer
Lobby Level

ACMT Pre-Symposium Registration / Information

7:00 am – 8:00 am
Grand Ballroom 3
Lobby Level

Continental Breakfast

8:00 am – 4:30 pm
Grand Ballroom 3
Lobby Level

ACMT Pre-Symposium: Music City Mixology: The High Notes and Low Notes of Booze and Drugs

Moderators: Andrea Carlson, MD

Andrew King, MD

Daniel Sessions, MD

Christina Hantsch, MD

Presentations:

*****Smooth Operator: Addiction, Criminal Behavior, and Recidivism*****

Christopher Holstege, MD

Always on the Mind: Neuroadaptations in Drug Use

Donna Seger, MD

After the Storm: Therapies to Maintain Sobriety from Alcohol

JoAn Laes, MD

The Shake: Management of Refractory Ethanol Withdrawal Cases

Michael Lynch, MD

The Hippy Hippy Shake: Toxicology of Cocktails

Daniel Sessions, MD

Detoxicity: The Toxicity of Medications for Withdrawal

Michele Burns, MD, MPH

Bold Face – indicates CE sessions

* Restricted to committee members *

** Presentation will not be audio recorded**

***Drunk Tank Case Studies:
Moderator Daniel Sessions, MD
Panelists:
Andy King, MD
JoAn Laes, MD
Michael Lynch, MD***

***In the Absinthe of Facts: Myths about Absinthe
Elizabeth Moore, DO***

***The Achy Breaky Heart: Chronic Effects on the Heart by
Methamphetamine and Other Stimulants
Stephanie Weiss, MD, PhD***

***We are the World: Insights and Controversies from
International Methanol Outbreaks
Jeffrey Brent, MD, PhD***

***Dying to Pass: Toxicity of Agents Used to Pass Urine Drug
Screening
Andrew King, MD***

***Who is Going to Save your Soul, Juul? New Vaping Trends
Fiona Garlich, MD***

***Drugs & Booze in the News
Moderator: Andrea Carlson, MD
Panelists:
Sean Bryant, MD
Nena Bowman, PharmD
Fiona Garlich, MD***

At the end of this session, the participant should be able to:

1. Discuss unique cases of criminal behavior associated with poisoning.
2. Consider a broader poisoning differential diagnosis.
3. Consider unique personalities associated with criminal poisoning.
4. Describe the changes in the CNS following drug use.
5. List the genetic changes that may occur following drug use.

Bold Face – indicates CE sessions

* Restricted to committee members *

** Presentation will not be audio recorded**

6. Compare the specific changes in the dopamine, dopamine transporter, immediate early genes and plasticity following drug use.
7. List the different pharmacotherapies for alcohol use disorder and how they can be implemented in a variety of healthcare settings.
8. Describe the pathophysiology of alcohol withdrawal.
9. Review evidence-based treatment of alcohol withdrawal.
10. Discuss novel approaches to the management of alcohol withdrawal.
11. Identify potential toxins in home prepared cocktail components.
12. Prepare for new toxicities from current cocktail trends.
13. Identify and treat toxicity from the combination of ethanol and other intoxicants.
14. Identify different agents used to treat opioid withdrawal.
15. Recognize potential adverse effects and toxicities of opioid withdrawal agents.
16. Explain management options for adverse effects and toxicities of opioid withdrawal agents.
17. Review the history of absinthe.
18. Identify common myths regarding absinthe toxicity.
19. Identify the major long-term cardiac effects of methamphetamine on the heart.
20. Compare and contrast the chronic cardiac effects of methamphetamine with other stimulants such as cocaine.
21. Understand the pathophysiology of methanol poisoning.
22. Treat a patient with methanol poisoning.
23. Understand the thresholds for treatment of methanol and ethanol poisoning.
24. Describe three of the most commonly employed methods to “pass” a urine drug screen.
25. Describe the potential toxicity of at least two of these methods.
26. Appreciate the epidemiology of e-cigarette use, and its burgeoning prevalence among adolescents.
27. Understand the potential toxicity of vaping, including risk of progression to traditional cigarette use.
28. Understand the unique risk of pediatric nicotine poisoning with exposure to e-cigarette fluid.

8:00 am – 5:00 pm

AACT Board Meeting

Sylvan Park

Meeting Space Level 2

Bold Face – indicates CE sessions

* Restricted to committee members *

** Presentation will not be audio recorded**

Monday, September 23, 2019 (continued)**Conference Schedule**

12:00 pm – 6:00 pm *ABAT Exam* (Part 1)
Melrose
Meeting Space Level 1

5:00 pm – 9:00 pm *ABAT Board Meeting* (Part 1)
Edgehill
Meeting Space Level 2

Bold Face – indicates CE sessions

* Restricted to committee members *

** Presentation will not be audio recorded**

Biologicals

Heather Young, MD

Genetic Terrorism

Jillian Theobald, MD, PhD

Radioactive Terrorism

Carol Iddins, MD

Risk Communications

Vivi Siegel, MD

Mass Hysteria

Timothy Jones, MD

The Greatest Threat Panel Discussion

Emily Kiernan, DO

Frank Walter, MD

Sean Bryant, MD

Steve Bird, MD

Sue Gorman, MD

Annie Arens, MD

Vikhyat Bebarta, MD

William Eggleston, PharmD

Heather Young, MD

Jillian Theobald, MD, PhD

Carol Iddins, MD

Vivi Siegel, MD

Timothy Jones, MD

Bold Face – indicates CE sessions

* Restricted to committee members *

** Presentation will not be audio recorded**

At the end of this session, the participant should be able to:

1. Integrate knowledge of some of the recent worldwide events involving nerve agents into your practice.
2. Compare and contrast the decisions made when identifying and treating patients from nerve agent attacks.
3. Recite the role a toxicologist can play in a nerve agent attack.
4. Identify and discuss the physical property that many of chemical weapons of opportunity share.
5. List the relative toxicity of various chemical weapons of opportunity.
6. Identify and discuss the fundamental therapeutic modality for many chemical weapons of opportunity.
7. Recite the pharmacology of atropine.
8. Discuss atropine utilization in times of terrorism and war.
9. Compare and contrast the strengths and weaknesses of various alternative antimuscarinic agents when atropine is in short supply.
10. Describe the basic structure of oximes.
11. List the limitations to oxime use.
12. Identify scenarios when oxime use is indicated.
13. Describe the ways in which the Strategic National Stockpile may respond to an incident.
14. Describe the SNS CHEMPACK program.
15. Describe the history of the development and use of organoarsenic compounds as chemical warfare agents.
16. Describe the clinical effects of exposure to organoarsenic compounds.
17. Recite the proposed mechanism of toxicity of organoarsenic compounds.
18. Determine the clinical effects of Cyanide /H₂S poisoning.
19. Describe the new therapies for cyanide.
20. Describe the new therapies for H₂S.
21. Describe the toxicities associated with gases used as chemical warfare agents or deterrents.
22. Discuss the history of toxic gases as agents of chemical warfare.
23. Develop a monitoring and treatment plan for patient's presenting after a toxic gas exposure.
24. Identify clinical syndromes consistent with bioterrorism agents.
25. Select appropriate personal protective equipment and post-exposure prophylaxis for bioterrorism agents.

Bold Face – indicates CE sessions

* Restricted to committee members *

** Presentation will not be audio recorded**

26. Compare gene editing techniques.
27. Discuss the potential for large scale genomic bioterrorism.
28. Examine the necessary public health response to a genetic bioterrorism attack.
29. Describe radiological sources/devices that may cause medical issues to individuals or to the public.
30. Describe situations in which some of these sources have been used to cause or attempt to cause injuries/illnesses.
31. Identify the six principles of Crisis and Emergency Risk Communication.
32. Apply CERC principles to communicating about chemical exposures.
33. Prepare a simple communications plan related to chemical exposure.
34. Identify factors associated with psychogenic illness.
35. Implement effective responses to mitigate adverse consequences from a mass psychogenic event.

8:00 am – 2:00 pm *ABAT Exam* (Part 2)
Melrose
Meeting Space Level 1

8:00 am – 5:00 pm *ACMT Board Meeting*
Midtown 1
Meeting Space Level 2

9:00 am – 5:00 pm *ABAT Board Meeting* (Part 2)
Edgehill
Meeting Space Level 2

12:00 pm – 5:00 pm *AAPCC Board Meeting* (Part 1)
Sylvan Park
Meeting Space Level 2

1:00 pm – 6:00 pm NACCT Conference Registration / Information
Grand Ballroom Foyer
Lobby Level

1:00 pm – 5:00 pm Exhibitor Set - Up
Broadway Ballroom
Meeting Space Level 1

Bold Face – indicates CE sessions

* Restricted to committee members *

** Presentation will not be audio recorded**

1:00 pm – 5:00 pm Poster Session I Set-Up - Abstracts # 17-116
Broadway Ballroom
Meeting Space Level 1

4:00 pm – 7:00 pm AAPCC SPI Advisory Council
Midtown 2
Meeting Space Level 2

5:00 pm – 10:00 pm * AAPCC Accreditation Committee Meeting *
Midtown 3
Meeting Space Level 2

5:00 pm – 6:00 pm AAPCC Benchmarking / QA Meeting
Sylvan Park
Meeting Space Level 2

5:00 pm – 6:00 pm PEC Steering Committee
5 Points
Meeting Space Level 1

5:00 pm – 7:00 pm ACMT Medical Toxicology:
Grand Ballroom 3 *21st Annual Clinical Pathophysiology Competition*
Lobby Level *Moderator: Jeffrey R. Suchard, MD*

At the end of the session, the participant should be able to:

1. Generate a good differential diagnosis of anion gap metabolic acidosis.
2. Describe the management of several unique poisonings.
3. Identify potential pitfalls in the diagnostic approach to poisoned patients.

6:00 pm – 7:00 pm PEC Open Meeting
Melrose
Meeting Space Level 1

6:00 pm – 7:00 pm AAPCC Micromedex Joint Coding Committee
Sylvan Park
Meeting Space Level 2

Bold Face – indicates CE sessions

* Restricted to committee members *

** Presentation will not be audio recorded**

Tuesday, September 24, 2019, continued**Conference Schedule**

6:30 pm – 8:00 pm CAPCC Business Meeting
Midtown 1
Meeting Space Level 2

7:00 pm- 9:00pm AAPCC SPI Meet & Greet Reception
Offsite
George Jones Roof Top Lounge

7:00 pm -9:00 pm PEC Meet and Greet
Edgehill
Meeting Space Level 2

7:00 pm – 7:45 pm AACT Business & Membership Meeting
SoBro
Meeting Space Level 1

8:00 pm – 9:00 pm AACT Members' Reception and FAACT Induction Ceremony
SoBro *Moderator: Mark Kostic, MD, AACT President*
Meeting Space Level 1

Bold Face – indicates CE sessions

* Restricted to committee members *

** Presentation will not be audio recorded**

7:00 am – 6:00 pm NACCT Main Congress Registration / Information
Grand Ballroom Foyer
Lobby Level

7:00 am – 8:30 am Continental Breakfast
Grand Foyer
Lobby Level

7:30 am – 8:30 am AACT Envenomation Section
Belle Meade
Meeting Space Level 1

7:30 am – 8:30 am AAPCC Managing Directors
SoBro
Meeting Space Level 1

7:30 am – 8:30 am ACMT Quality Measures Workgroup
Midtown 1
Meeting Space Level 2

7:30 am – 8:30 am ACMT Membership Committee
Midtown 2
Meeting Space Level 2

7:30 am – 8:30 am ACMT Research Committee
Sylvan Park
Meeting Space Level 2

7:30 am – 8:30 am AAPCC Medical Directors
Germantown 4
Meeting Space Level 2

7:30 am – 8:30 am AACT Acute and Intensive Care Section
Midtown 3
Meeting Space Level 2

Bold Face – indicates CE sessions

* Restricted to committee members *

** Presentation will not be audio recorded**

7:30 am – 8:00 am AACT Geriatric Section
Germantown 3
Meeting Space Level 2

7:30 am- 8:30 am AACT Pediatric Section
Fisk 1
Hotel Level 2

7:30 am – 8:30 am AACT WMD Section
Edgehill
Meeting Space Level 2

8:00 am – 5:00 pm AAPCC: One - on - One NPDS Training
5 Points
Meeting Space Level 1

8:30 am – 12:30 pm Toxicology Fellowship Interest Group (Residents and medical students)
Melrose
Meeting Space Level 1

8:30 am – 9:30 am
Grand Ballroom
Lobby Level

NACCT Keynote Presentation:
Broken: My Story of Addiction and Redemption
Sponsored by Johnson & Johnson Consumer, Inc.
Moderators: Mark Kostic, MD, AACT President
Kirk Cumpston, DO, AACT President-Elect

Presenter: William Moyers

At the end of the session, the participant should be able to:

1. Identify the symptoms and problems caused by a substance use disorder.
2. Describe how to help somebody struggling with a substance use disorder.
3. Take steps to reduce the stigma of addiction and promote the power and possibility of recovery from it.

9:00 am – 4:00 pm Exhibits/Posters Session I - Abstracts # 17-116
Broadway Ballroom *Sponsored by: Rare Disease Therapeutics, Inc*
Meeting Space Level 1

Bold Face – indicates CE sessions

* Restricted to committee members *

** Presentation will not be audio recorded**

9:30 am – 11:00 am Authors with Posters - Abstracts # 17-116
Broadway Ballroom Refreshment Break
Meeting Space Level 1

11:00 am – 11:30 am Lightning Oral Presentations
Grand Ballroom 2 Moderator: Jon Cole, MD
Lobby Level 2

**# 158 Same Day Transportation for Opioid Use Disorder: Impact of the Crisis
Addiction Recovery Transportation (CART) Program, Andrew King, MD**

**# 254 Seizure Following Bupropion Insufflation: A National Poison Data System
Study, Ronald Kirschner, MD**

79 Characterization of acute exposures to cannabis resins, Matt Noble, MD

**# 251 Cannabis Use and High-Risk Substance Use Behaviors in the United States
Non-Medical Use of Prescription Drugs (NMURx) National Survey, Janette Iwanicki, MD**

At the end of the session, the participant should be able to:

1. Describe the successful hand off rate of a same-day referral and transportation program from the ED for patients with opioid-related diagnoses.
2. Characterize the incidence and onset of symptoms following bupropion insufflation abuse.
3. Discuss factors to consider in determining an appropriate observation period following bupropion insufflation.
4. Describe variability in poison center recommendations following bupropion insufflation.
5. Consider study data describing clinical effects associated with acute exposures to cannabis resins.
6. Describe cannabis use and other substance use behaviors in the United States Non-Medical Use of Prescription Drugs (NMURx) National Survey.

11:00 am – 11:30 am AAPCC: Artificial Intelligence, Machine Learning and NPDS
Grand Ballroom 1 Applications
Lobby Level Moderators: Julie Weber, BS Pharm
Mark Ryan, PharmD

Presenter: Tina Moen, PharmD

Bold Face – indicates CE sessions

* Restricted to committee members *

** Presentation will not be audio recorded**

At the end of the session, the participant should be able to:

1. Describe artificial intelligence opportunities in healthcare.
2. Leverage AI examples to envision AI strategy for their organizations.
3. Describe the strength of the combination of human + machine.

11:30- 12:30 pm ACMT Practice Symposium: The Role of Personalized
Grand Ballroom 1 *Medicine in Medical Toxicology Practice*
Lobby Level *Moderator: Christina Hantsch, MD*

Presenters: Dan Roden, MD
Sarah Van Driest, MD, PhD

At the end of the session, the participant should be able to:

1. Recite the role of generic variation in drug metabolism.
2. Compare the role of genetic variation in drug response.
3. Provide a conceptual overview of drug gene interactions.
4. Discuss specific examples of drugs metabolized by CYP2D6.
5. Describe availability and technical limitations of CYP2D6 testing.

11:30 am - 12:30 pm EAPCCT Scientific Symposium: Mechanistic Basic for
Grand Ballroom 2 *Assessing Human Health Risks from Chemical Warfare*
Lobby Level *Agents and Pesticides*
Moderator: Martin Wilks, MD, PhD

Presenters: **Horst Thiermann, MD**
Martin Wilks, MD, PhD

At the end of the session, the participant should be able to:

1. Explain why forensic verification of sulphur mustard poisoning has to rely on specific biomarkers.
2. Explain why treatment of sulphur mustard poisoned patients consumes large resources.
3. Explain why treatment of sulphur mustard poisoning in the very early phase might be dangerous for medical personnel.
4. Discuss the differences in approach between international agencies when assessing toxicology data.

Bold Face – indicates CE sessions

* Restricted to committee members *

** Presentation will not be audio recorded**

5. Explain the controversy about carcinogenic properties of the herbicide glyphosate.

11:30 am – 12:30 pm **AACT Fellow/Trainee Research Platforms**
 Grand Ballroom 3 **Moderators: Mark Kostic, MD**
 Lobby Level **Kennon Heard, MD, PhD**

Systematic variations in the anion gap complicate the management of poisoned patients, Josh Wang, MD

Pharmaceutical Exposures in Pregnant Women Reported to the National Poison Data System from 2013 to 2018, Laurie Halm, MD

Home Brew: A systematic approach to the evaluation of auto-brewery syndrome, Kim Aldy, DO

What's in a handful? Interpreting a commonly used unit of measurement, Tim Rianprakaisang, MD

*****A simple approximation of the QT nomogram, Steven Fishburn, MD*****

At the end of the session, the participant should be able to:

1. Recognize five sources of systematic or random bias that render the anion gap an imprecise diagnostic tool.
2. Describe common pharmaceutical exposures in pregnant women reported to poison centers in the United States.
3. Describe auto-brewery syndrome.
4. Predict the variability in estimation of “handful” as it relates to various pill sizes.
5. Illustrate a simple approximation of the QT nomogram for assessing drug induced QT prolongation.

11:30 am – 12:30 pm **PEC: Prevention Response to the Opioid Epidemic**
 SoBro **Moderator: Carissa McBurney, MPA**
 Meeting Space Level 1

Presenters: Wendy Blair Stephan, PhD, MPH, CHES
Jared O'Connor, MS, MPH
Laura Morehouse, MPH, CHES

Bold Face – indicates CE sessions

* Restricted to committee members *

** Presentation will not be audio recorded**

At the end of the session, the participant should be able to:

1. Converse how a poison center may partner with a needle exchange program to address opioid overdoses in a community.
2. Recognize potential challenges when participating in harm reduction initiatives such as needle exchange programs.
3. Discuss the safety benefits of disposing unused medications.
4. Describe how Google maps is used to list medication take back locations.
5. Describe the process of designing and implementing an opioid overdose education program in rural counties.

12:00 pm – 1:30 pm *AACT Clinical Toxicology Editorial Board Meeting*
Midtown 1
Meeting Space Level 2

12:30 pm – 1:30 pm Lunch on Your Own

12:30 pm – 1:30 pm *Tox Collaborative AC Project*
Belle Meade
Meeting Space Level 1

12:30 pm – 1:30 pm AAPCC Government Affairs Committee
Wedgewood
Meeting Space Level 2

12:30 pm – 2:00 pm *AHLS Board Meeting*
Edgehill
Meeting Space Level 2

12:30 pm – 1:30 pm ACMT Women in Tox Section
Midtown 2
Meeting Space Level 2

Bold Face – indicates CE sessions

* Restricted to committee members *

** Presentation will not be audio recorded**

12:30 pm – 1:30 pm ACMT Industry Section
Sylvan Park
Meeting Space Level 2

12:30 pm – 1:30 pm ACMT ToxIC Network
Germantown 4
Meeting Space Level 2

12:30 pm – 1:30 pm AACT Herbs and Dietary Supplements Section
Germantown 3
Meeting Space Level 2

1:30 pm – 3:30 pm **Platform Session I: Abstracts # 1-8**
Grand Ballroom 2 **Moderators: Kirk Cumpston, DO**
Lobby Level **Martin Wilks, MD, PhD**

#1 Assessment of microRNA-122 for Drug-Induced Liver Injury in Patients with Muscle Injury, Jada (Yu) Zhang MS, PhD

#2 Efficacy of oral administration of sodium thiosulfate and glycine in a large, swine model of oral cyanide toxicity, Patrick Ng, MD

#3 Accuracy of patient exposure history compared with analytical findings for those reporting use of synthetic cannabinoid receptor agonists, Simon Thomas MD

*****#4 The Effect of 4-Methylpyrazole on Oxidative Metabolism of Acetaminophen in Human Volunteers, A. Min Kang MD*****

#5 Effectiveness of antivenom for definite red-bellied black snake (Pseudechis porphyriacus) envenomation, Geoffrey Isbister, MD

#6 Severe delayed QT prolongation: a novel risk factor for adverse cardiovascular events from acute drug overdose, Eleanor Roberts, MD

Bold Face – indicates CE sessions

* Restricted to committee members *

** Presentation will not be audio recorded**

#7 Associations of Prenatal Manganese with Visual-Motor Skills in Adolescence,
Bryan Stierman, MD, MPH

#8 Antiemetics Effectiveness for Cannabinoid Hyperemesis Syndrome (CHS)
Emergency Department (ED) Encounters, Susan Hammerman, BS

At the end of the session, the participant should be able to:

1. Compare aminotransferases with microRNA 122 could be a more reliable biomarker to identify drug-induced liver injury in patients with muscle injury.
2. Explain the basic pathophysiology of oral cyanide poisoning.
3. Explain the basic therapeutic targets for treatment of oral cyanide poisoning.
4. Describe the sensitivity and specificity of patient history in determining analytically-confirmed exposure to synthetic cannabinoids.
5. Quantify the numbers of separate drugs of misuse found in samples from users declaring exposure to a single substance.
6. Describe an effect of fomepizole on acetaminophen metabolism.
7. Recite the importance of early antivenom in snake envenomation.
8. Review how severe QTc prolongation (>500 ms) is be a predictor of adverse cardiovascular events (ACVE).
9. Describe clinical predictors of ACVE from drug overdose.
10. Consider whether dsQTp after drug exposure is an independent predictor for ACVE.
11. Identify the clinical effects associated with manganese exposure in children.
12. Recognize that subclinical effects from manganese can occur with lower level exposure to heavy metals.
13. Identify and evaluate relative effectiveness of various types of antiemetics used by a large Colorado urban academic ED to treat CHS.

1:30 pm – 2:30 pm

SoBro

Meeting Space Level 1

PEC: Achieving Cultural Appropriateness in Health
Education Programs

Moderators: Laura Morehouse, MPH, CHES
Carissa McBurney, MPA

Presenter: Tiffany Israel, MSSW

At the end of the session, the participant should be able to:

1. Discuss how to develop awareness of cultural issues among different populations.
2. Identify the different strategies used in health education to achieve a level of cultural appropriateness.

Bold Face – indicates CE sessions

* Restricted to committee members *

** Presentation will not be audio recorded**

3. Discuss application of culturally appropriate strategies to health education interventions.

2:30 pm – 3:30 pm

SoBro

Meeting Space Level 1

PEC: Establishing Evidence-Based Programs for Poison Education

***Moderators: Laura Morehouse, MPH, CHES
Carissa McBurney, MPA***

***Presenters: Alexa Steverson, MA
Lauren Longo, MSPH***

At the end of the session the participant should be able to:

1. Dissect the elements of evidence-based public health within a poison prevention educational campaign.
2. Appraise the degree to which evidence-based public health is applied in personal practice.
3. Define the characteristics of an evidence-based public health approach.
4. Preview tools available to assist the public health educator in applying an evidence-based framework to practice.
5. Apply the educational components of a case study of an evidence-based poison prevention campaign to their own work.

3:30 pm – 3:45 pm

Broadway Ballroom

Meeting Space Level 1

Refreshment Break

3:45 pm – 4:45 pm

Grand Ballroom 1

Ballroom Level

**AACT Herbal Dietary Supplement Special Interest Section
Symposium: An update on CBD**

Moderator: Michael Hodgman, MD

***Presenters: George Sam Wang, MD
Michael Hodgman, MD***

At the end of the session the participant should be able to:

1. Contrast the differences between hemp and marijuana.
2. Describe the currently regulatory status of cannabidiol in the United States.

Bold Face – indicates CE sessions

* Restricted to committee members *

** Presentation will not be audio recorded**

3. Discuss potential health benefits or medical indications where cannabidiol may be of benefit.
4. Describe the difference, by legal definition, between hemp and cannabis.
5. Discuss the legal limbo of cannabidiol as far as being considered a food or a dietary supplement.

**3:45 pm – 4:45 pm
Grand Ballroom 2
Lobby Level**

AACT: Diversity and Inclusion in Toxicology/Women in Toxicology

Moderator: Meghan Spyres, MD

Presenters: Meghan Spyres, MD

Jennie Buchanan, MD

*****Michelle Ruhu, MD*****

Karen Simone, PharmD

At the end of the session the participant should be able to:

1. Review of gender distribution of presentations, lecturers, panelists, awards/grants given to NACCT/ACMT members 2015-2019.
2. Discussion of challenges of being a female in toxicology.
3. Discussion of benefits of being a female in toxicology.
4. Describe the trend of women in toxicology over the past 30 years.

**3:45 pm – 4:45 pm
Grand Ballroom 3
Lobby Level**

AAPCC Best Practice Symposium: Remote Workers and the Poison Center Environment: Making Work from Home Work

Moderator: Jamie Nisbet, RN

Presenters: Erin Pallasch, PharmD

George Bachman, BS Pharm

Carol DesLauriers, PharmD

Gaylord Lopez, PharmD

At the end of the session the participant should be able to:

1. List the benefits and detriments to CSPI job satisfaction in centers that utilize remote working.
2. Describe ways remote working directly benefits poison center services.

Bold Face – indicates CE sessions

* Restricted to committee members *

** Presentation will not be audio recorded**

3. Identify the type of strategies and policies necessary for a successful remote working program.
4. Compare the policies and procedures that have been developed for staff managing poisoning cases from home, with policies and procedures when working in the poison center.
5. List potential pros and cons for managing poisoning cases from outside the poison center setting.

3:45 pm – 4:45 pm

SoBro

Meeting Space Level 1

PEC: Preparing for the Accreditation Application

Moderators: Laura Morehouse, MPH, CHES

Carissa McBurney, MPA

Presenters: Christina DeRienzo, MHIT

Lee Livermore, BAA

At the end of the session the participant should be able to:

1. Identify how to align your goals and objectives with your need's assessment data.
2. Determine priority populations and justify why they were selected.
3. Assess your education outreach and impact with proper evaluation tools.

4:00 pm – 4:30 pm

Broadway Ballroom

Meeting space Level 1

Posters Session I Tear Down – Abstracts # 17-116

4:45 pm – 5:45 pm

Grand Ballroom 1

Lobby Level

CAPCC Symposium: Medical Assistance in Dying: A

Canadian Perspective and Drug-ectomies: Deprescribing in your older patients

Moderators: Margaret Thompson, MD

Ryan Chaung, MD

Presenters: Tom Rich, MD, CCFP-EM, FCFP

Howard An, MD

Bold Face – indicates CE sessions

* Restricted to committee members *

** Presentation will not be audio recorded**

At the end of the session the participant should be able to:

1. Recount the MAID program in Canada.
2. List the medications being used for MAID procedures in Canada.
3. Discuss polypharmacy, adverse drug events, and the scope of the problem.
4. Discuss aging and its effect on pharmacokinetics.
5. Discuss an approach to deprescribing with example medications to consider.

4:45 pm – 5:45 pm
Grand Ballroom 2
Lobby Level

ABAT Scientific Symposium: Naloxone Distribution Grand Programs, Toxicology, & Pharmacology
Moderators: Howard McKinney Jr. PharmD
Rachel Gorodetsky, PharmD

Presenters: William Eggleston, PharmD
Rachel Schult, PharmD

At the end of the session the participant should be able to:

1. Describe barriers to naloxone access and alternative distribution models in North America.
2. Assess the risks and benefits of expanded access to naloxone, high dose naloxone, naloxone devices, and proposed alternatives.
3. Develop patient care strategies for increasing access to medication assisted treatment and harm reduction resources in North America.

4:45 pm – 5:45 pm
Grand Ballroom 3
Lobby Level

AACT Occupational and Environmental Symposium: Occupational Exposure to Fentanyl and Synthetic Cannabinoids - Science beyond the Hype Programs, Toxicology, & Pharmacology
Moderator: Michael Greenberg, MD

Presenters: **Robert Palmer, PhD**
Michael Moss, MD
Allison Muller, PharmD

Bold Face – indicates CE sessions

* Restricted to committee members *

** Presentation will not be audio recorded**

At the end of the session the participant should be able to:

1. Contrast the history, previous recommendations, actions by law enforcement agencies, unions, public health agencies with today.
2. Describe potential routes of exposure in handling novel psychoactive substances and risk of toxicity.
3. Make reasonable recommendations for PPE for first responders based on potential for toxicity.
4. State two elements for building trust and credibility in risk communication.
5. List two key risk communication skills for communicating to non-toxicology audiences.

5:00 pm – 5:45 pm Poster Session II Set Up - Abstracts # 117-213
Broadway Ballroom
Meeting Space Level 1

6:00 pm – 7:00 pm NACCT Opening Reception
Germantown Ballroom
Meeting Space Level 2

7:00 pm – 8:30 pm AAPCC Quiz Bowl, SPI Awards and Scientific Poster Awards
Grand Ballroom 1 Quiz Bowl Moderator: Prashant Joshi, MD
Lobby Level

7:30 pm – 10:00 pm * NACCT Sponsors and Friends Dinner *
Offsite

7:00 pm – 8:00 pm ABAT Business Meeting
SoBro
Meeting Space Level 1

8:00 pm – 9:30 pm ABAT Members' Reception
Wedgewood
Meeting Space Level 2

Bold Face – indicates CE sessions

* Restricted to committee members *

** Presentation will not be audio recorded**

Thursday, September 26, 2019**Conference Schedule**

7:00 am – 5:00 pm Grand Foyer Lobby Level	NACCT Main Congress Registration / Information
7:00 am – 8:30 am Grand Foyer Lobby Level	Continental Breakfast
7:00 am – 8:00 am Wedgewood Meeting Level 2	SAVASANA AWAKENS "ROOTS to RISE: Yoga Class with George Bachman
7:30 am – 8:30 am Grand Ballroom 3 Lobby Level	AAPCC Toxicall Users Group
7:30 am – 8:30 am SoBro Meeting Space Level 1	AAPCC ToxSentry Data Group
7:30 am – 8:30 am Belle Meade Meeting Space Level 1	AACT Scientific Committee
7:30 am – 8:30 am Sylvan Park Meeting Space Level 2	ACMT Medical Toxicology Fellow-in-Training Association
7:30 am – 8:30 am Midtown 2 Meeting Space Level 2	ACMT Practice Committee
7:30 am – 8:30 am Midtown 3 Meeting Space Level 2	ACMT Fellowship Directors Committee
7:30 am – 8:00 am Midtown 1 Meeting Space Level 2	AACT History Section

Bold Face – indicates CE sessions

* Restricted to committee members *

** Presentation will not be audio recorded**

7:30 am – 8:30 am AACT Envenomation Section
Edgehill
Meeting Space Level 2

7:30 am – 8:30 am AACT Forensic Section
Germantown 2
Meeting Space Level 2

7:30 am – 8:30 am AAPCC Surveillance Team
Melrose
Meeting Space Level 1

8:00 am – 5:00 pm AAPCC: One - on - One NPDS Training
5 Points
Meeting Space Level 1

8:00 am – 8:30 am AACT Occupational and Environmental Section
Midtown 1
Meeting Space Level 2

8:30 am – 9:00 am **AACT Career Achievement Award: From there to here –
Grand Ballroom 1 40 years and counting**
Moderator: Mark Kostic, MD

Presenter: Mary Ann Howland, PharmD

At the end of the session, the participant should be able to:

1. Describe the benefits of being mentored and mentoring.
2. Relay the teamwork that is necessary when editing a textbook.

8:30 am – 9:30 am PEC: How to Create, Fund, and Produce Educational
SoBro Materials
Meeting Space Level 1 *Moderators: Laura Morehouse, MPH, CHES*
Carissa McBurney, MPA

Presenters: Sherrie Pace, MS
Alysia Longmire, OCPC
Maureen Roland, RN, BSN

Bold Face – indicates CE sessions

* Restricted to committee members *

** Presentation will not be audio recorded**

At the end of the session, the participant should be able to:

1. Summarize examples of how to create educational content based on needs assessments.
2. Summarize ways to disseminate education programs to increase reach.
3. Cite examples of how to seek outside funding for the creation of educational materials.
4. Cite examples of how to produce quality education materials in a variety of formats.

9:00 am – 10:30 am
Grand Ballroom 2
Lobby Level

*****Clinical Toxicology Recommendation Collaborative (AACT, APAMT, AAPCC, ACMT, CAPCC, EAPCCT) New guidelines on GI decontamination with Activated Charcoal*****

Moderator: Robert S. Hoffman, MD

Presenters: Lotte Hoegberg, MSc., PhD
David Wood, MD
Sophie Goesslin, MD
Ingrid Berling, BMed
Rittirak Othing, MD

At the end of the session, the participant should be able to:

1. Explain the concept of Indirectness of pharmacokinetic and toxicokinetic data compared to patient centered outcomes.
2. Categorize the evidence for SDAC administration based on the nature of the toxin.
3. Distinguish the kinetic differences between MDAC and SDAC based on the nature of the toxin.
4. Appraise the evidence regarding benefit of AC administration with various post-ingestion delays.
5. Create the risk portion of a formal risk: benefit analysis for activated charcoal administration.

Bold Face – indicates CE sessions

* Restricted to committee members *

** Presentation will not be audio recorded**

9:00 am – 4:00 pm Exhibits/ Poster Session II - Abstracts #117-213
Broadway Ballroom *Sponsored by: Rare Disease Therapeutics, Inc*
Meeting Space Level 1

9:00 am – 10:30 am **SPI Jeopardy**
Grand Ballroom 1 ***Moderator: Edward Bottei, MD***
Lobby Level

At the end of the session, the participant should be able to:

1. Identify diagnostic clues to help recognize uncommon exposures.
2. List diagnostic criteria for certain common exposures or syndromes.
3. Discuss strategies for managing uncommon exposures.

9:00 am – 10:00 am **ACMT Fellows-in-Training Visiting Professor Lecture –**
Grand Ballroom 3 ***Teaching Toxicology to Other Professionals: The How and***
Lobby Level ***Why of Continuing Medical Education***
 Moderator: Andrew King, MD

Presenter: Allison Muller, PharmD

Panelists: Nena Bowman, PharmD
Andrea Carlson, MD

At the end of the session, the participant should be able to:

1. List 1 benefit of getting involved in CME in each of the three career stages.
2. State 2 examples of potential conflicts in CME content.
3. Identify at least 1 venue for CME-faculty opportunities.

10:00 am – 11:00 am **AACT Envenomation Special Interest Section Symposium-**
Grand Ballroom 3 ***Brown Recluse Spider Envenomation***
Lobby Level ***Moderator: Nicklaus Brandehoff, MD***

Presenters: Stephen Thornton, MD
Donna Seger, MD

Bold Face – indicates CE sessions

* Restricted to committee members *

** Presentation will not be audio recorded**

At the end of the session, the participant should be able to:

1. Explain how the diagnosis of brown recluse spider bites are made.
2. Compare and contrast the management strategies of two regional poison centers.
3. Summarize a feasible approach to a brown recluse spider bite that present with local or systemic symptoms.
4. Describe the pathophysiology in hemolysis of brown recluse spider bites.
5. Identify cutaneous lesions caused by BRSB.
6. Compare and contrast management controversies of treatment of cutaneous lesions and hemolysis.

10:00 am – 10:30 am

SoBro

Meeting Space Level 1

****PEC: AAPCC Updates****

Moderators: Laura Morehouse, MPH, CHES

Carissa McBurney, MPA

Presenter: Tara Robertson, JD

At the end of the session, the participant should be able to:

1. Describe AAPCC's initiatives aimed at raising national awareness of poison control centers.
2. Describe AAPCC's initiatives aimed at preventing unintentional poisonings.

10:30 am – 11:00 am

SoBro

Meeting Space Level 1

PEC: HRSA Updates

Moderators: Laura Morehouse, MPH, CHES

Carissa McBurney, MPA

Presenter: Jeremey Nelson

At the end of the session, the participant should be able to:

1. Identify HRSA's current projects related to the poison center promotion.
2. Recommend ways HRSA can support poison prevention programs.
3. Understand the 2019 achievements of the Poison Help campaign.

Bold Face – indicates CE sessions

* Restricted to committee members *

** Presentation will not be audio recorded**

10:30 am – 11:00am Lightning Oral Presentations
Grand Ballroom 2 Moderator: Jillian Theobald, MD, PhD
Lobby Level

Morbidity and Seizures Associated with e-cigarette Exposures, Dan Spyker, MD, PhD

Seniors and SUDS (Single-Use Detergent Sacs): A review of the National Poison Center Database, Kim Aldy, DO, MBA

Piloting Exposure Category Call Volume Algorithms to Improve National Public Health Surveillance Using Poison Control Center Call Data, Royal Law, PhD

Antecedent Activities, Exposure Site and Demographics of Crotalid Envenomation's Reported to One Southeastern United States Poison Center, 2014-2018, Michael Beuhler, MD

At the end of the session, the participant should be able to:

1. Appreciate the increase in the numbers of seizures reported in association with e-cigarettes compared to other nicotine delivery systems.
2. Recognize the risk of single-use detergent sac exposure in the elderly.
3. Describe how the US Centers for Disease Control and Prevention has been piloting new algorithms to improve national surveillance using poison center data.
4. Describe the results of the piloting project.
5. Understand the activities preceding snake bites in the American southeast and how they differ from rattlesnake bites in the American west.

11:00 am – 12:00 pm Authors with Posters – Abstracts # 117-213
Broadway Ballroom Refreshment Break
Meeting Space Level 1

12:00 pm – 1:00 pm Lunch on your Own

12:00 pm – 1:00 pm **Tox Collaborative QT Project* *
Belle Meade
Meeting Space Level 1

Bold Face – indicates CE sessions

* Restricted to committee members *

** Presentation will not be audio recorded**

12:00 pm – 1:00 pm *AAPCC Committee Chairs & Fatality Review Luncheon*
Midtown 2
Meeting Space Level 2

12:00 pm – 1:30 pm AACT Clinical Toxicology Senior Editorial Board Meeting
Sylvan Park
Meeting Space Level 2

12:00 pm – 1:00 pm *AACT Fellows- in-Training and Leaders Luncheon*
Midtown 3
Meeting Space Level 2

12:00 pm – 1:00 pm ACMT Medical Toxicology Foundation Board Meeting
Midtown 1
Meeting Space Level 2

12:00 pm – 1:00 pm ACMT Addiction Medicine Committee
Edgehill
Meeting Space Level 2

12:00 pm – 1:00 pm *JMT Editorial Board Meeting*
Germantown 2
Meeting Space Level 2

1:00 pm – 2:00 pm **Platform Session II: Abstracts #9-12**
Grand Ballroom 2 **Moderators: Julie Weber, BS Pharm**
Lobby Level **Brandon Wills, DO**

#9 National assessment of loperamide abuse awareness and ability to restrict purchase at retail pharmacies, Ryan Feldman, MD, Erik Everton, PharmD Candidate

10 Impact of ASTM Safety Standard on Accidental Exposures to Liquid Laundry Packets in Children, Kate Reynolds, MPH

#11 Modern Lethality Rate of Suspected Cyclopeptide Mushroom Poisoning in the US: The Power of Supportive Care! Jonathan de Olano, MD

Bold Face – indicates CE sessions

* Restricted to committee members *

** Presentation will not be audio recorded**

#12 Rates of adequate reversal and symptoms of opioid withdrawal syndrome (OWS) in patients treated initially with low dose naloxone or high dose naloxone,
Roy Purssell, MD

At the end of the session, the participant should be able to:

1. Demonstrate the prevalence of awareness of loperamide abuse and current state of ability to restrict sale throughout the US.
2. Recite the impact of product safety changes on pediatric accidental poison center exposures to liquid laundry packets.
3. Explain how the modern mortality rate for cyclopeptide mushroom poisoning in the US is less than historical standards.
4. Contrast the patients treated initially with low dose naloxone or high dose naloxone by comparing the different rates of adequate reversal and withdrawal symptoms

1:00 pm – 2:00 pm
Grand Ballroom 1
Lobby Level

AACT Radiation Special Interest Section Symposium: The Role of Poison Centers in Radiation Emergencies
Moderators: Emily Kiernan, DO
Justin Loden, PharmD

Presenters: Ziad Kazzi, MD
Rebecca Bruccoleri, MD
Carol Iddins, MD

At the end of the session, the participant should be able to:

1. List activities in radiation emergencies where PCs and clinical toxicologists are involved.
2. Discuss challenges facing PCs and clinical toxicologists in their roles related to radiation emergencies.
3. Discuss potential solutions to the above problems.

1:00 pm – 2:00 pm
SoBro
Meeting Space Level 1

PEC: Strategies for Social Media Success
Best Practice for Reaching Tweens & Teens
Moderator: Carissa McBurney, MPA
Laura Morehouse, MPH, CHES

Presenter: Brie Burge, BS Communications

Bold Face – indicates CE sessions

* Restricted to committee members *

** Presentation will not be audio recorded**

At the end of the session, the participant should be able to:

1. Summarize why the inclusion of graphics is important to improving engagement on social media.
2. Explain how to create effective graphics utilizing free and inexpensive web-based tools.
3. Describe how to employ Facebook advertising to promote their poison centers, including audience targeting.

1:00 pm – 2:00 pm
Grand Ballroom 3
Lobby Level

**AAPCC SPI Clinical Practice Symposium: Don't Go
Breakin' My Heart: Cardiac Medications and the Poisoned
Patient**
Moderator: Jamie Nisbet, RN

Presenters: Anthony Pizon, MD
Elizabeth Scharman, PharmD

At the end of the session, the participant should be able to:

1. Differentiate between common cardiovascular medications seen in overdose situations.
2. Identify different therapies that may be used to treat the patient with a cardiovascular drug overdose.
3. Recognize pros and cons to therapies commonly used to treat the patient with a cardiovascular drug overdose.

2:00 pm – 3:00 pm
Grand Ballroom 2
Ballroom Level

AACT Scientific Symposium: Is CAOS causing CHAOS
Moderator: Robert S. Hoffman, MD

Presenters: Marco Sivilotti, MD
Donna Seger, MD
Sophie Goesslin, MD
Robert S. Hoffman, MD

Bold Face – indicates CE sessions

* Restricted to committee members *

** Presentation will not be audio recorded**

At the end of the session, the participant should be able to:

1. Rate the evidence to support various intravenous n-acetylcysteine (NAC) regimens in acetaminophen (paracetamol, APAP) poisoning.
2. Develop an algorithm to individualize delivery to APAP poisoned patients.
3. Rate the evidence to support the need for multiple APAP concentrations in poisoned patients.
4. Use an evidence-based approach to develop a set of recommendations for gastrointestinal decontamination in APAP poisoned patients.

2:00 pm – 3:00 pm
Grand Ballroom 1
Lobby Level

AAPCC Scientific Symposium - “Moonshine: Past, Present, Future”
Moderator: Julie Weber, BS Pharm

Presenter: Greg Eidam II, BS Engineering

At the end of the session, the participant should be able to:

1. Recite the history of moonshine and how it is intertwined with prohibition.
2. Describe the process of alcohol production and concerns for the home distiller.
3. Contrast the benefits of the evolution of the still and the risks of making moonshine.

2:30 pm – 3:30 pm
SoBro
Meeting Space Level 2

PEC: Using Health Behavior Theories to Design and Evaluate a Poison Prevention Program
Moderators: Laura Morehouse, MPH, CHES
Carissa McBurney, MPA

Presenter: Emily Paterson, BS, CHES

At the end of the session, the participant should be able to:

1. Discuss the different health behavior theories that act as foundations for program planning and development.
2. Apply the principles of health education theories to poison prevention program development.
3. Analyze how theories help planners identify suitable audiences, methods for fostering change, and outcomes for evaluation.

Bold Face – indicates CE sessions

* Restricted to committee members *

** Presentation will not be audio recorded**

2:00 pm – 3:30 pm
Grand Ballroom 3
Lobby Level

AACT/ACMT Pediatric Special Interest Section
Symposium - *The Effects of Prenatal Addiction on Children*
from Conception through Early Childhood
Moderator: Christine Murphy, MD

Presenters: Christine Murphy, MD
Elizabeth Hines, MD
Abby Montague, MD

At the end of the session, the participant should be able to:

1. Describe the effects of common drugs of abuse on fetal development.
2. Interpret common neonatal drug screens.
3. Recognize effects common drugs of abuse have on early childhood development.

3:30pm – 3:45 pm
Broadway Ballroom
Meeting Space Level 1

Refreshment Break

3:45 pm – 4:45 pm
Grand Ballroom 1
Lobby Level

AACT Forensics Special Interest Section Symposium: *The*
Toxicology of Criminal Activities
Moderator: Ram Rao, MD

Presenters: Rama Rao, MD
Sabra Botch-Jones, MS, MA, D-ABFT-FT

At the end of the session, the participant should be able to:

1. Compare the common presentations of drug facilitated sexual assault.
2. Appreciate the substantial gaps in understanding the handling and testing of samples.
3. Provide toxicologists with information to reduce medical and forensic miscommunication to survivors of suspected sexual assault.
4. Describe the analytical instrumentation utilized in forensic toxicology laboratories and the differences that may exist between clinical and forensic analysis.
5. List the challenges that face forensic toxicologist with the novel drugs and testing limitations and how these challenges may also impact clinical toxicology.

Bold Face – indicates CE sessions

* Restricted to committee members *

** Presentation will not be audio recorded**

3:45 pm – 4:45 pm
Grand Ballroom 2
Lobby Level

ACMT Scientific Symposium - Tune in to That Cardiac Channel: Details on Calcium and Sodium
Moderator: Heather Long, MD

Presenters: Donna Seger, MD
Katherine Murray, MD
Björn Knollman, MD, PhD

At the end of the session, the participant should be able to:

1. Describe the structure and function of the cardiac sodium channel.
2. Describe the clinical and ECG manifestations of cardiac sodium channel blocker toxicity.
3. Elucidate the effects of pH on the cardiac sodium channel and channel blockers.
4. Understand the mechanism of action of calcium channel blockers.
5. Describe the difference between calcium channel blockers in terms of mechanisms in overdose.
6. Compare the physiology of calcium channel blockers in various organ systems.

3:45 pm – 4:45 pm
Grand Ballroom 3
Lobby Level

AAPCC Veterinary Symposium - Drug Testing and Doping in Dogs and Racehorses
Moderator: Tina Wismer, DVM

Presenter: Lynn Hovda, BS Pharm, DVM

At the end of the session, the participant should be able to:

1. List the different types of drug testing in racehorses and when they are utilized.
2. Contrast the pros/cons of point of care ethylene glycol tests for dogs.
3. Identify several different drugs used as doping agents in racehorses.
4. Recognize the difference between customary use of therapeutic drugs and misuse or abuse of the same drug.

4:00 pm – 4:30 pm
Broadway Ballroom
Meeting Space Level 1

Poster Session II Tear Down – Abstracts # 117- 213

Bold Face – indicates CE sessions

* Restricted to committee members *

** Presentation will not be audio recorded**

4:30 pm – 5:00 pm Broadway Ballroom Meeting Space Level 2	Poster Session III Set Up - Abstracts # 214 - 310
4:45 pm – 6:00 pm Grand Ballroom 3 Lobby Level	AAPCC Town Hall and Annual AAPCC Awards
6:30 pm – 10:30 pm Offsite	Tin Roof on Broadway Dinner and Live Music <i>Sponsored by Boston Scientific/ BTG</i> (Purchased ticket required)

Bold Face – indicates CE sessions

* Restricted to committee members *

** Presentation will not be audio recorded**

7:00 am – 3:45 pm Grand Ballroom Foyer Lobby Level	NAACT Main Congress Registration / Information
7:00 am – 8:30 am Grand Ballroom Foyer Lobby Level	Continental Breakfast
7:30 am – 8:30 am Germantown 4 Meeting Space Level 2	ACMT Legal and Consultative Section
7:30 am – 8:30 am Germantown 1 Meeting Space Level 2	ACMT International Section and Committee
7:30 am – 8:30 am Belle Meade Meeting Space Level 1	ACMT Pediatrics Section
7:30 am – 8:30 am Sylvan Park Meeting Space Level 2	AACT Trainee and Student Section
8:00 am – 3:45 pm 5 Points Meeting Space Level 1	AAPCC: One - on - One NPDS Training
8:30 am – 10:00 am Ballroom 1 Lobby Level	AACT Acute/Intensive Care Special Interest Section Grand Symposium <i>Moderators: Bryan Hayes, PharmD</i> <i>Jenny Lu, MD</i> <i>Presenters: John Downs, MD, MPH</i> <i>Diana Dean, MD</i> <i>Kartik Shah, MD</i>

Bold Face – indicates CE sessions

* Restricted to committee members *

** Presentation will not be audio recorded**

Panelists: Diane Calello, MD
Nena Bowman, PharmD
Sarah Shafer, MD
Donna Seger, MD

At the end of the session, the participant should be able to:

1. Discuss the benefits versus risks of repeated use of sodium bicarbonate boluses in refractory sodium channel blockade.
2. Discuss the benefits versus risks of early administration of lipid emulsion rescue therapy.
3. Discuss the indications and timing for extracorporeal membrane oxygenation (ECMO) in severe cardiotoxicity.
4. Identify and manage methylxanthine toxicity.
5. Discuss when to initiate hemodialysis in methylxanthine toxicity.
6. Discuss strategies to manage cases of methylxanthine toxicity in a timely fashion.
7. Compare the benefits and risks of N-acetylcysteine in non-acetaminophen liver failure in the pediatric population.
8. Recite the common laboratory interferences with the salicylate and ethanol assays.

8:30 am – 10:00 am
Grand Ballroom 2
Lobby Level

APAMT Symposium: Charcoal is the New Black
Moderator: Geoff Isbister, MD

Presenters: Angela Chiew, BSci(Med), MBBS
Geoff Isbister, MD
Nanayakkarawasam K Anjana Silva,
MBBS, PhD

At the end of the session, the participant should be able to:

1. Recognize clinical situations in which benefit from charcoal is likely.
2. Recite the evidence indicates about risks from charcoal.
3. Define the effect of activated charcoal on the pharmacokinetics of drugs.
4. Describe the overall trends of charcoal usage in Sri Lankan hospitals for acute poisoning over last 15 years.
5. Describe the trends of charcoal usage in Sri Lankan hospitals for different types of acute poisoning over last 15 years.
6. Describe the outcomes of charcoal usage in Sri Lankan hospitals for acute poisoning over last 15 years.

Bold Face – indicates CE sessions

* Restricted to committee members *

** Presentation will not be audio recorded**

Presenter: Joanne Perley, MPH

1. Describe community and national resources and how to access them.
2. Contrast how suicide is a national and local public health problem.

1. Discuss issues and management of those issues in challenging cases or circumstances.
2. Compare tools and aids such as references, charts, educational initiatives to foster enhanced learned information.

10:00 am – 10:30 am
Grand Ballroom 1
Lobby Level

Lightning Oral Presentations
Moderator: Joao Delgado, MD

A systematic review and meta-ananlysis of alternative dosing to the FDA approved 3-bag regimen, Christian Garcia, MD

**** Presentation will not be audio recorded****

Is that really the level? On the imprecision of commonly ordered toxicological assays", Khameinei Ali, MD

At the end of the session, the participant should be able to:

1. Describe trends in intentional overdose amongst youth for the last 10 years.
2. Name three important drugs used frequently in intentional overdose.
3. Recognize substance that may cause absent brainstem reflexes, leading a physician to consider brain death.
4. Appreciate the frequency with which this occurs in regards to specific substances.
5. Provide a differential diagnosis for future consults pertaining to toxins that can cause profound coma.
6. Consider the risks and common side effects associated with the FDA approved.
7. Recognize the effect of analytical variation on the results of common toxicologic assay.

10:00 am – 10:30 am
Grand Ballroom 2
Lobby Level

AAPCC Symposium: Department of Homeland Security:
Drug Trafficking Interdiction
Moderator: Julie Weber, BS Pharm

Presenter: Mark Sutter, MD

At the end of the session, the participant should be able to:

1. Dictate how the DHS can interact with Poison Centers and public health.
2. Recite how to access information regarding drugs destined to your area.

1030 am – 11:30 am
Broadway Ballroom
Meeting Space Level 1

Authors with Posters / Abstracts # 214-310
Refreshment Break

11:30 am – 12:30 pm

Lunch on Your Own

11:30 am - 12:30 pm
Edgehill
Meeting Space Level 2

PEC 2020 NACCT Planning Meeting

11:30am – 12:30 pm
Germantown 1
Meeting Space Level 2

ACMT Government Section

Bold Face – indicates CE sessions

* Restricted to committee members *

** Presentation will not be audio recorded**

11:30 am – 12:30 pm AAPCC PoisonHelp.org Committee
Belle Meade
Meeting Space Level 1

11:30 am – 12:30 pm AAPCC Public Health Committee
Sylvan Park
Meeting Space Level 2

11:30 am – 12:30 pm AACT Radiation Section
Germantown 4
Hotel Level 2

12:30 pm – 1:30 pm **Platform Session III: Abstracts #13 - 16**
Grand Ballroom 1 Moderators: Geoff Isbister, MD
Lobby Level Jeanna Marraffa, PharmD

13 Efficacy of Intravenous Hydroxocobalamin Versus Control for Treatment of Severe Methanethiol Toxicity in a Swine (*Sus scrofa*) Model, Joseph Maddry, MD

#14 Intravenous phytonadione administered orally for warfarin-related coagulopathy, Jordan Rice, PharmD

#15 Five Decades of Global Chemical Terror Attacks: Data to Inform Training and Preparedness, Michael DeLuca, MD

#16 Drug-Specific Anti-Xa Levels Before and After Infusion of Coagulation Factor Xa (recombinant), inactivated-zhzo (Andexxa®) for Bleeding in Patients Anticoagulated with Apixaban or Rivaroxaban: A Quality Improvement Project, Kelly Considine, PharmD

At the end of the session, the participant should be able to:

1. Describe the impact of hydroxocobalamin on vital signs in a pig model of methanethiol poisoning.
2. Describe the impact of hydroxocobalamin on mortality in a pig model of methanethiol poisoning.
3. Describe the limitations of this study.
4. Discuss the rationale and paucity of data comparing intravenous phytonadione given orally compared to oral phytonadione tablets.

Bold Face – indicates CE sessions

* Restricted to committee members *

** Presentation will not be audio recorded**

5. Describe the efficacy of the oral use of both products in warfarin-related coagulopathy.
6. Discuss pertinent toxicological indications for orally administered phytonadione.
7. Appreciate trends in the types of chemical weapons used in terror attacks over the past 50 years, and in particular since 2001.
8. Identify characteristics of worldwide chemical weapons terror events that can inform training and policy making.
9. Discuss the use of coagulation factor Xa (recombinant), inactivated-zhzo (Andexxa®) for bleeding at a Level I Trauma Hospital.
10. Contrast the pre- and post-infusion antiXa levels and how they compared to Annexa-4.
11. Define considerations for restrictions of use for coagulation factor Xa (recombinant), inactivated-zhzo (Andexxa®).

12:30 pm – 2:30 pm
Grand Ballroom 2
Lobby Level

****Review of the 2019 Medical Toxicology LLSA Articles****

Moderator: Jakub Furmaga, MD

Presenters: Brandon Wills, DO
Brandon Warrick, MD
Jakub Furmaga, MD
Evan Schwarz, MD

At the end of the session, the participant should be able to:

1. Discuss various important updates in the medical field of toxicology.
2. Describe important clinical evaluations and treatments for various toxicologic conditions

12:30 pm – 1:30 pm
Grand Ballroom 3
Lobby Level

SPI Roundtable Symposium

Moderator: Randy Badillo, RN

Presenters: Caroline Werner, RN
Charisse Pizarro-Osilla, RN

Panelists: William Banner, MD
Kristie Edelen, PharmD

Bold Face – indicates CE sessions

* Restricted to committee members *

** Presentation will not be audio recorded**

At the end of the session, the participant should be able to:

1. Discuss possible effects seen in a massive ibuprofen ingestion.
2. Discuss rescue therapies for critically ill poisoned patients.
3. Compare the 3 phases of nausea and vomiting in CHS.
4. Describe the treatment management in CHS.

12:30 pm – 1:30 pm

Germantown 2

Meeting Level 2

PEC Swap and Share

Moderators/Presenters:

Laura Morehouse, MPH, CHES

Carissa McBurney, MPA

At the end of the session, the participant should be able to:

1. Recognize innovative and creative poison related public education programs.
2. List successful public education poison materials.
3. Identify successful poison prevention campaigns.
4. Recognize innovative and creative poison related public education programs.
5. List successful public education poison materials.
6. Identify successful poison prevention campaigns.

1:30 pm – 2:30 pm

Grand Ballroom 2

Lobby Level

****ACMT Fellows-in-Training Roundtable:**

Developing an Inpatient Medical Toxicology Service **

Moderator: Jeffrey Brent, MD, PhD

Panelists: Richard Clark, MD

Daniel Brooks, MD

At the end of the session, the participant should be able to:

1. List the details of starting a medical toxicology service.
2. Describe how to maintain a division of Medical Toxicology.
3. Recite how a medical toxicologist can interact with an academic medical center.

1:30 pm – 2:30 pm

SoBro

Meeting Space Level 1

PEC: Emergent Drugs of Abuse

Moderators: Laura Morehouse, MPH, CHES

Carissa McBurney, MPA

Presenters: William Eggleston, PharmD

Scott Phillips, MD

Bold Face – indicates CE sessions

* Restricted to committee members *

** Presentation will not be audio recorded**

At the end of the session, the participant should be able to:

1. Describe the proposed indications for kratom and the current landscape of use in North America.
2. Compare and contrast the potential risks and benefits of kratom use.
3. Describe the international market place for illicit drugs.
4. List the most common global production sites.
5. Recite resources for information on international drug trafficking.

1:30 pm – 2:30 pm
Grand Ballroom 1

****The UK Novichok Experience Symposium****
Moderator: David Gummin, MD

Presenter: Paul Russell, MD

At the end of the session, the participant should be able to:

1. Describe the basic pharmacology and action of nerve agent.
2. List the principles of treating an unknown chemical substance and the specific therapeutic options for treating nerve agent poisoning.
3. Recite on how an incident of this nature a multi-agency response is required to protect the patient, the attending staff and the community.

2:30 pm – 2:45 pm
Broadway Ballroom
Meeting Space Level 1

Refreshment Break

2:45 pm – 3:45 pm
Grand Ballroom 1
Lobby Level

AACT Tox History Special Interest Section Symposium –
Toxicology in Country Music
Moderator: Anna Arroyo Plasencia, MD

Presenters: Denese Britt, RN
Adam Overberg, PharmD, BCPS

At the end of the session, the participant should be able to:

1. Explain the grass roots history of Moonshine.
2. Identify the necessary ingredients required to make Moonshine.
3. State whether Moonshine is a legal or illegal product.
4. Describe the history of drug references in popular music.
5. Appraise the drug references in several country music songs.

Bold Face – indicates CE sessions

* Restricted to committee members *

** Presentation will not be audio recorded**

2:45 pm – 3:45 pm
Grand Ballroom 2
Lobby Level

Society of Toxicology Symposium
Moderator: Ken McMartin, PhD

Presenters: Chris Vulpe, MD, PhD
Diana Dow-Edwards PhD

At the end of the session, the participant should be able to:

1. Explain fundamentals of CRISPR technology.
2. Describe current and potential utilization of CRISPR in toxicology.
3. Articulate the endocannabinoid system in brain, the CB receptors and the role of endocannabinoids in brain physiology.
4. Understand the effects of marijuana on adolescent brain development including cognition, mental health and addiction.
5. Understand the dose-response nature of the effects of marijuana on the brain.

2:45 pm – 3:45 pm
SoBro
Meeting Space Level 1

PEC: Strategies to Strengthen the Poison Control Center
Message for Diverse Multilingual Communities
Moderators: Laura Morehouse, MPH, CHES
Carissa McBurney, MPA

Presenters: Emilio Saenz, BS
Cassandra Vega, MPH
Cristina Thomas, M.Ed.
Lizbeth Petty, MPH

At the end of the session, the participant should be able to:

1. Describe how collaboration with promotoras (community health workers) can improve outreach to non-English speaking communities.
2. Describe how promotoras can also be used as a resource when translating materials.
3. Describe the needed steps when translating materials, including working with outside translation companies and community providers.
4. Describe strategies to field test translated materials.
5. Identify the range of organizations that educators can collaborate with to provide poison prevention information to non-English speaking communities.
6. Describe the methods that educators can use to relay poison prevention messaging to non-English speaking communities.

Bold Face – indicates CE sessions

* Restricted to committee members *

** Presentation will not be audio recorded**

7. Identify the range of organizations that educators can collaborate with to provide poison prevention information to non-English speaking communities.
8. Describe the methods that educators can use to relay poison prevention messaging to non-English speaking communities.

2:45 pm –3:30 pm

Broadway Ballroom

Meeting Space Level 1

Poster Session III Tear Down – Abstracts # 214-310

Bold Face – indicates CE sessions

* Restricted to committee members *

** Presentation will not be audio recorded**

8:00 am – 1:00 pm
Fisk 2/Hotel Level 2

*AAPCC Board Meeting (Part 2) *

Bold Face – indicates CE sessions

* Restricted to committee members *

** Presentation will not be audio recorded**